12:00 AM
Jan 25, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aloxi regulatory update

Japan approved Aloxi palonosetron to prevent chemotherapy-induced nausea and vomiting (CINV) in patients with cancer. Taiho Pharmaceutical Co. Ltd., a subsidiary...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >